Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | casein kinase 2, alpha subunit, putative | 0.1879 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1879 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1879 | 1 | 0.5 |
Leishmania major | casein kinase II, putative | 0.1879 | 1 | 0.5 |
Giardia lamblia | Kinase, CMGC CK2 | 0.1879 | 1 | 0.5 |
Plasmodium vivax | unspecified product | 0.1879 | 1 | 0.5 |
Entamoeba histolytica | protein kinase domain containing protein | 0.1879 | 1 | 0.5 |
Plasmodium falciparum | casein kinase 2, alpha subunit | 0.1879 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1879 | 1 | 0.5 |
Entamoeba histolytica | casein kinase, putative | 0.1879 | 1 | 0.5 |
Onchocerca volvulus | 0.1864 | 0.9909 | 0.5 | |
Trichomonas vaginalis | CMGC family protein kinase | 0.1879 | 1 | 0.5 |
Echinococcus granulosus | casein kinase ii subunit alpha | 0.1879 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1879 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1879 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1879 | 1 | 0.5 |
Trypanosoma brucei | Casein kinase II | 0.1879 | 1 | 1 |
Echinococcus multilocularis | casein kinase ii subunit alpha | 0.1879 | 1 | 0.5 |
Loa Loa (eye worm) | CMGC/CK2 protein kinase | 0.1879 | 1 | 1 |
Trypanosoma cruzi | casein kinase II, putative | 0.1879 | 1 | 0.5 |
Toxoplasma gondii | CMGC kinase, CK2 family | 0.1879 | 1 | 0.5 |
Schistosoma mansoni | protein kinase | 0.1879 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MCC (ADMET) | = 70 uM | Cytotoxicity in human HeLa cells after 24 hrs by XTT assay | ChEMBL. | 23841482 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.